Literature DB >> 11995774

Diagnosis and treatment of premenstrual dysphoria.

Elias Eriksson1, Björn Andersch, Hoi Por Ho, Mikael Landén, Charlotta Sundblad.   

Abstract

Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome afflicting 5% to 10% of all fertile women. Cardinal symptoms--appearing regularly between ovulation and menstruation and disappearing within a few days after the onset of the bleeding--are depressed mood, tension, affect lability, and irritability. Of these symptoms, irritability is often the most prominent. Serotonin reuptake inhibitors (SRIs), but not nonserotonergic antidepressants, reduce the symptoms of PMD effectively. The onset of action of SRIs is much shorter when used for PMD than when used for depression, enabling women with PMD to restrict medication use to the luteal phase of the cycle (so-called intermittent treatment). The findings that SRIs are effective for PMD--and that sexual dysfunction is the most frequent side effect during long-term treatment--both lend support for the hypothesis that a major role for brain serotonin is to modulate sex steroid-driven behavior.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11995774

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

Review 1.  Current update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

2.  Exploring sex and gender differences in sleep health: a Society for Women's Health Research Report.

Authors:  Monica P Mallampalli; Christine L Carter
Journal:  J Womens Health (Larchmt)       Date:  2014-06-23       Impact factor: 2.681

Review 3.  Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?

Authors:  Uriel Halbreich; P M Shaughn O'Brien; Elias Eriksson; Torbjörn Bäckström; Kimberly A Yonkers; Ellen W Freeman
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Mental health literacy towards depression among non-medical students at a Malaysian university.

Authors:  Tahir M Khan; Syed A Sulaiman; Mohamed A Hassali
Journal:  Ment Health Fam Med       Date:  2010-03

Review 5.  Transcription factor AP-2 and monoaminergic functions in the central nervous system.

Authors:  M Damberg
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

6.  Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.

Authors:  Kimberly A Yonkers; Susan G Kornstein; Ralitza Gueorguieva; Brian Merry; Kari Van Steenburgh; Margaret Altemus
Journal:  JAMA Psychiatry       Date:  2015-10       Impact factor: 21.596

Review 7.  Sex steroid-related candidate genes in psychiatric disorders.

Authors:  Lars Westberg; Elias Eriksson
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

Review 8.  Update on research and treatment of premenstrual dysphoric disorder.

Authors:  Joanne Cunningham; Kimberly Ann Yonkers; Shaughn O'Brien; Elias Eriksson
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

9.  Premenstrual syndrome.

Authors:  Kimberly Ann Yonkers; P M Shaughn O'Brien; Elias Eriksson
Journal:  Lancet       Date:  2008-04-05       Impact factor: 79.321

10.  Premenstrual dysphoria and luteal stress in dominant-social-status female macaques.

Authors:  Mingqi Qiao; Qitao Zhao; Sheng Wei; Huiyun Zhang; Haijun Wang
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-28       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.